Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) saw an uptick in trading volume on Monday . 5,739 shares were traded during mid-day trading, a decline of 5% from the previous session's volume of 6,045 shares.The stock last traded at $10.97 and had previously closed at $10.82.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on PHAR shares. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 20th. Oppenheimer boosted their target price on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research report on Friday, March 14th.
Read Our Latest Research Report on Pharming Group
Pharming Group Stock Performance
The firm has a market cap of $706.15 million, a PE ratio of -51.90 and a beta of 0.02. The business has a 50 day simple moving average of $10.38 and a two-hundred day simple moving average of $9.41. The company has a quick ratio of 2.00, a current ratio of 2.76 and a debt-to-equity ratio of 0.39.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. The firm had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. As a group, equities research analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
